POSA39 Cost-Effectiveness Analysis of Nivolumab for the Adjuvant Treatment of Patients with Resected Esophageal Cancer (EC) or Gastroesophageal Junction Cancer (GEJC) in Canada

Autor:	A Amadi, K Toor, E Keeney, H Thom, P Singh, I Kim, E Mameri
Rok vydání:	2022
Předmět:	Health Policy Public Health Environmental and Occupational Health
Zdroj:	Value in Health. 25:S40
ISSN:	1098-3015
DOI:	10.1016/j.jval.2021.11.185
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a5deb9e4cbf38c81dd5b05bd3155cac4 https://doi.org/10.1016/j.jval.2021.11.185 Zobrazit plný text záznamu Full Text from ScienceDirect